Article info

Original research
Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease

Authors

  1. Correspondence to Dr Albina Nowak, Department of Endocrinology and Clinical Nutrition, University Hospital Zurich and University of Zurich, 8091 Zürich, Switzerland; albina.nowak{at}usz.ch
View Full Text

Citation

Nowak A, Beuschlein F, Sivasubramaniam V, et al
Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease

Publication history

  • Received July 13, 2020
  • Revised November 6, 2020
  • Accepted December 3, 2020
  • First published January 25, 2021.
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.